Hideho Okada Selected Research

Very Late Antigen Receptors

9/2009

Brain tumor immunotherapy with type-1 polarizing strategies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideho Okada Research Topics

Disease

101	Neoplasms (Cancer) 01/2022 - 05/2002
73	Glioma (Gliomas) 01/2022 - 05/2002
34	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 09/2002
22	Brain Neoplasms (Brain Tumor) 01/2022 - 06/2004
7	Central Nervous System Neoplasms 01/2022 - 08/2004
6	Melanoma (Melanoma, Malignant) 11/2013 - 08/2004
3	Ependymoma 01/2018 - 01/2013
3	Astrocytoma (Pilocytic Astrocytoma) 01/2018 - 08/2005
3	Neoplasm Metastasis (Metastasis) 07/2013 - 05/2002
3	Sarcoma (Soft Tissue Sarcoma) 03/2007 - 10/2003
2	Diffuse Intrinsic Pontine Glioma 12/2020 - 01/2018
2	Inflammation (Inflammations) 01/2020 - 11/2015
2	Disease Progression 01/2019 - 06/2012
2	Testicular Neoplasms (Testicular Cancer) 01/2019 - 11/2018
2	Bites and Stings (Sting) 04/2015 - 12/2014
2	Experimental Melanoma 02/2012 - 11/2004
1	Poliomyelitis (Polio) 01/2020
1	Oligodendroglioma 01/2018
1	Cytokine Release Syndrome 01/2017
1	Meningioma (Meningiomas) 12/2016

Drug/Important Bio-Agent (IBA)

43	AntigensIBA 01/2022 - 06/2002
40	VaccinesIBA 01/2022 - 06/2002
26	Peptides (Polypeptides)IBA 01/2022 - 09/2002
18	EpitopesIBA 01/2018 - 09/2002
14	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2005
12	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 05/2002
11	Chimeric Antigen ReceptorsIBA 01/2022 - 08/2012
8	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022 - 08/2005
8	Interleukin-4 (Interleukin 4)IBA 10/2009 - 12/2002
7	poly ICLCIBA 01/2022 - 02/2007
7	Messenger RNA (mRNA)IBA 01/2018 - 01/2007
7	Monoclonal AntibodiesIBA 12/2014 - 02/2007
7	CytokinesIBA 02/2012 - 10/2003
6	epidermal growth factor receptor VIIIIBA 01/2022 - 01/2013
6	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2002
6	Lysine (L-Lysine)FDA Link 01/2018 - 02/2007
6	Protein Subunit VaccinesIBA 01/2018 - 11/2009
6	gallium arsenide (GaAs)IBA 12/2016 - 12/2007
6	Integrin alpha4beta1 (VLA-4)IBA 10/2009 - 02/2007
5	Carboxymethylcellulose Sodium (Polycell)FDA Link 07/2014 - 02/2007
5	OvalbuminIBA 07/2007 - 08/2004
4	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2013
4	ChemokinesIBA 04/2017 - 02/2008
4	LigandsIBA 10/2016 - 02/2007
4	SurvivinIBA 01/2016 - 01/2007
4	Poly I-CIBA 07/2014 - 09/2009
4	InterferonsIBA 01/2012 - 08/2004
3	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 04/2017
3	FluorocarbonsIBA 01/2021 - 01/2013
3	FluorineIBA 01/2021 - 01/2013
3	AntibodiesIBA 01/2020 - 08/2011
3	Cancer VaccinesIBA 12/2015 - 02/2009
3	Celecoxib (Celebrex)FDA Link 08/2014 - 04/2011
3	Therapeutic UsesIBA 08/2014 - 05/2002
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 08/2014 - 05/2013
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 08/2014 - 04/2011
3	Histocompatibility Antigens Class IIBA 06/2012 - 01/2007
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 02/2012 - 06/2006
3	MicroRNAs (MicroRNA)IBA 02/2012 - 06/2009
3	InterleukinsIBA 12/2007 - 07/2003
3	Interleukin-13 Receptor alpha2 SubunitIBA 01/2007 - 09/2002
3	Complementary DNA (cDNA)IBA 04/2006 - 07/2003
2	ErbB Receptors (EGF Receptor)IBA 01/2021 - 09/2005
2	Oxygen (Dioxygen)IBA 01/2021 - 01/2013
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 08/2011
2	dipinacoline glutamateIBA 12/2020 - 01/2018
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2020 - 06/2016
2	AcidsIBA 01/2019 - 10/2003
2	ProteomeIBA 01/2019 - 11/2018
2	HLA-A Antigens (HLA-A)IBA 01/2019 - 07/2012
2	RNA (Ribonucleic Acid)IBA 12/2017 - 06/2012
2	Biological ProductsIBA 12/2016 - 01/2012
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2016 - 04/2006
2	EnzymesIBA 11/2015 - 12/2007
2	Antiviral Agents (Antivirals)IBA 12/2014 - 01/2012
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2013 - 03/2007
2	Interferon Type IIBA 05/2013 - 07/2003
2	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 07/2012 - 09/2002
2	Transforming Growth Factor beta (TGF-beta)IBA 11/2009 - 08/2003
2	Fas Ligand Protein (Fas Ligand)IBA 08/2005 - 08/2003
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2005 - 11/2004
1	Mutant Proteins (Protein, Mutant)IBA 01/2022
1	alpha-hydroxyglutarateIBA 01/2022
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2021
1	HLA-A*24:02 antigenIBA 01/2019
1	protoporphyrin IXIBA 01/2019
1	IMA950IBA 01/2018
1	Methionine (L-Methionine)FDA Link 01/2018
1	MethylcholanthreneIBA 01/2018
1	Histones (Histone)IBA 01/2018
1	LuciferasesIBA 12/2017
1	EmulsionsIBA 12/2017

Therapy/Procedure

64	Immunotherapy 01/2022 - 08/2003
45	Therapeutics 01/2022 - 05/2002
7	Drug Therapy (Chemotherapy) 10/2020 - 08/2011
6	Radiotherapy 10/2020 - 12/2007
4	Injections 09/2010 - 07/2003
2	Intravenous Infusions 01/2022 - 01/2021
1	Combined Modality Therapy 01/2021
1	Chemoradiotherapy 01/2020